Management of erectile dysfunction by the geriatrician

Journal of the American Geriatrics Society

Volumn 45, Issue 10, 1997, Pages 1240-1246

  Godschalk, Michael F ^a   Sison, Alfredo ^a   Mulligan, Thomas ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hunter Holmes McGuire Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAPAVERINE; PROSTAGLANDIN E1;

DEVICE; DIAGNOSTIC APPROACH ROUTE; GERIATRIC CARE; HUMAN; IMPOTENCE; INTRACAVERNOUS DRUG ADMINISTRATION; MALE; PATHOPHYSIOLOGY; PENIS ERECTION; REVIEW; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SEXUAL INTERCOURSE;

EID: 0030923476     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1997.tb03778.x     Document Type: Review

References (67)

1. Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
2. Mulligan T, Moss CR. Sexuality and aging in male veterans: A cross-sectional study of interest, ability, and activity. Arch Sex Behav 1991;20:17-25.
3. Slag MF, Morley JE, Elson MK et al. Impotence in medical clinic outpatients. JAMA 1983;249:1736-1740.
4. Cunningham GR, Hirshkowitz M. Inhibition of steroid 5 alpha-reductase with finasteride: Sleep-related erections, potency, and libido in healthy men. J Clin Endocnnol Metab 1995;80:1934-1940.
5. Schiavi RC, Schreiner-Engel P, White D, Mandeli J. The relationship between pituitary-gonadal function and sexual behavior in healthy aging men. Psychosom Med 1991;53:363-374.
6. Burris AS, Banks SM, Carter CS et al. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992;13:297-304.
7. Nankin HR, Lin T, Osterman J. Chronic testosterone cyprionate therapy in men with secondary impotence. Fertil Steril 1986;46:300-307.
8. Bancroft J, Wu FCW. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983;12:59-66.
9. Steers WD. Neural control of penile erection. Semin Urol 1990;8:66-79.
10. Wagner G, Gerstenberg T, Levin RJ. Electrical activity of corpus cavernosum during flaccidity and erection of the human penis: A new diagnostic method? J Urol 1989;142:723-725.
11. Lugg JA, Gonzalez-Cadavid NF, Rajfer J. The role of nitric oxide in erectile function. J Androl 1995;16:2-4.
12. Burnett AL. Nitric oxide control of lower genitourinary tract functions: A review. Urology 1995;45:1071-1083.
13. Said SI. Nitric Oxide and vasoactive intestinal peptide: Cotransmitters of smooth muscle relaxation. NIPS 1992;7:181-183.
14. Makhlouf GM, Grider JR. Nonadrenergic noncholinergic inhibitory transmitters of the gut. NIPS 1993;8:195-199.
15. Newman HF, Northup JD. Mechanism of human penile erection: An overview. Urology 1981;17:399-408.
16. Wespes E, Schulman C. Venous impotence: Pathophysiology, diagnosis and treatment. J Urol 1993;149:1238-1245.
17. Fournier GR Jr., Juenemann KP, Lue TF, Tanagho EA. Mechanisms of venous occlusion during canine penile erection: An anatomic demonstration. J Urol 1987;137:163-167.
18. Newman HF, Reiss H, Northup JD. Physical basis of emission, ejaculation, and orgasm in the male. Urology 1982;19:341-350.
19. The American Urologic Association Erectile Dysfunction Clinical Guidelines Panel. Report on the treatment of organic erectile dysfunction. Baltimore: American Urological Society, 1996.
20. Nahoul K, Roger M. Age-related decline of plasma bioavailable testosterone in adult men. J Steroid Biochem Mol Biol 1990;35:293-299.
21. Vermeulen A. Clinical Review 24: Androgens in the aging male. J Clin Endocrinol Metab 1991;73:221-224.
22. Veldhuis JD, Urban RJ, Lizarralde G et al. Attenuation of luteinizing hormone secretory burst amplitude as a proximate basis for the hypoandrogenism of healthy aging in men. J Clin Endocrinol Metab 1992;75:52-58.
23. Mulligan T, Katz PG. Why aged men become impotent. Arch Intern Med 1989;149:1365-1366.
24. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985;1:181-184.
25. Rosen MP, Greenfield AJ, Walker TG et al. Cigarette smoking: An independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence. J Urol 1991;145:759-763.
26. Morley JE, Korenman SG, Kaiser FE et al. Relationship of penile brachial pressure index to myocardial infarction and cerebrovascular accidents in older men. Am J Med 1988;84:445-448.
27. Azadzoi KM, Goldstein I. Erectile dysfunction due to atherosclerotic vascular disease: The development of an animal model. J Urol 1992;147:1675-1681.
28. Wespes E, Moreira de Goes P, Schulman C. Vascular impotence: Focal or diffuse penile disease. J Urol 1992;148:1435-1436.
29. Jevtich MJ, Khawand NY, Vidic B. Clinical significance of ultrastructural findings in the corpora cavernosa of normal and impotent men. J Urol 1990;143:289-293.
30. Azadzoi KM, Siroky MB, Goldstein I. Study of etiologic relationship of arterial atherosclerosis to corporal veno-occlusive dysfunction in the rabbit. J Urol 1996;155:1795-1800.
31. Brock GB, Lue TF. Drug-induced male sexual dysfunction. An update. Drug Saf 1993;8:414-426.
32. Drugs that cause sexual dysfunction: An update. Med Lett Drugs Ther 1992;34:73-78.
33. Kroner B, Mulligan T, Briggs G. Effect of frequently prescribed cardiovascular medications on sexual function. A pilot study. Ann Pharmacother 1993;27:1329-1332.
34. Mills TM, Stopper VS, Wiedmeier VT. Effects of castration and androgen replacement on the hemodynamics of penile erection in the rat. Biol Reprod 1994;51:234-238.
35. Chamness SL, Ricker DD, Crone JK et al. The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat. Fertil Steril 1995;63:1101-1107.
36. Lugg JA, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995;136:1495-1501.
37. Mulligan T, Schmitt B. Testosterone for erectile failure. J Gen Intern Med 1993;8:517-521.
38. Impotence. NIH Consensus Statement 1992;10:1-33.
39. Mulligan T, Iranmanesh A, Gheorghiu S et al. Amplified nocturnal luteinizing hormone (LH) secretory burst frequency with selective attenuation of pulsatile (but not basal) testosterone secretion in healthy aged men: Possible Leydig cell desensitization to endogenous LH signaling - A Clinical Research Center study. J Clin Endocrinol Metab 1995;80:3025-3031.
40. Govier FE, McClure RD, Kramer-Levien D. Endocrine screening for sexual dysfunction using free testosterone determinations. J Urol 1996;156:405-408.
41. Akpunonu BE, Mutgi AB, Federman DJ et al. Routine prolactin measurement is not necessary in the initial evaluation of male impotence. J Gen Intern Med 1994;9:336-338.
42. Morales A, Bain J, Ruijs A et al. Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy. Int J Impot Res 1996;8:95-97.
43. Korenman SG, Viosca SP, Kaiser FE et al. Use of a vacuum tumescence device in the management of impotence. J Am Geriatr Soc 1990;38:217-220.
44. Cookson MS, Nadig PW. Long-term results with vacuum constriction device. J Urol 1993;149:290-294.
45. Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982;2:938.
46. Zentgraf M, Ludwig G, Ziegler M. How safe is the treatment of impotence with intracavernous autoinjection? Eur Urol 1989;16:165-171.
47. Hu K-N, Burks C, Christy WC. Fibrosis of tunica albuginea: Complication of long-term intracavernous pharmacological self-injection. J Urol 1987;138:404-405.
48. Lakin MM, Montague DK, VanderBrug Medendorp S et al. Intracavernous injection therapy: Analysis of results and complications. J Urol 1990;143:1138-1141.
49. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996;334:873-877.
50. Godschalk MF, Chen J, Katz PG, Mulligan T. Prostaglandin E1 as treatment for erectile failure in elderly men. J Am Geriatr Soc 1994;42:1263-1265.
51. Chen J, Godschalk M, Katz PG, Mulligan T. The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction. J Urol 1995;153:80-81.
52. Chen J, Godschalk MF, Katz PG, Mulligan T. Incidence of penile pain after injection of a new formulation of prostaglandin E1. J Urol 1995;154:77-79.
53. Linet OI, Neff LL. Intracavernous prostaglandin E1 in erectile dysfunction. Clin Invest 1994;72:139-149.
54. Porst H. The rationale for prostaglandin E1 in erectile failure: A survey of worldwide experience. J Urol 1996;155:802-815.
55. Chen J, Godschalk M, Katz PG, Mulligan T. Peyronie's-like plaque after penile injection of prostaglandin E1. J Urol 1994;152:961-962.
56. Waldhauser M, Schramek P. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol 1988;140:525-527.
57. Gheorghiu D, Godschalk M, Gheorghiu S, Mulligan T. Slow injection of prostaglandin E1 decreases associated penile pain. Urology 1996;47:903-904.
58. Padma-Nathan H, Hellstrom WJ, Kaiser FE et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997;336:1-7.
59. Dittrich A, Albrecht K, Bar-Moshe O, Vandendris M. Treatment of pharmacological priapism with phenylephrine. J Urol 1991;146:323-324.
60. Muruve N, Hosking DH. Intracorporeal phenylephrine in the treatment of priapism. J Urol 1996;155:141-143.
61. Yohimbine for male sexual dysfunction. Med Lett Drugs Ther 1994;36:115-116.
62. Reid K, Morales A, Harris C et al. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet 1987;2:421-423.
63. Morales A, Condra M, Owen JA et al. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol 1987;137:1168-1172.
64. Abber JC, Lue TF, Luo JA et al. Priapism induced by chlorpromazine and trazodone: Mechanism of action. J Urol 1987;137:1039-1042.
65. Kurt U, Ozkardes H, Altug U et al. The efficacy of anti-serotoninergic agents in the treatment of erectile dysfunction. J Urol 1994;152:407-409.
66. Lance R, Albo M, Costabile RA, Steers WD. Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review. Urology 1995;46:117-120.
67. Adaikan PG, Ng SC, Chan C, Ratnam SS. Oral trazodone in the treatment of total secondary impotence in a diabetic patient. Br J Urol 1991;68:212-213.